Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2024 | Real-world application of the MSDA test to monitor disease progression in MS

Ferhan Qureshi, SVP – Biomarker R&D, Octave Bioscience, Menlo Park, CA, discusses the real-world application of the Multiple Sclerosis Disease Activity (MSDA) test, a blood test using multiple proteins to monitor disease activity in MS. He highlights a retrospective analysis of 90 patients showing that a high MSDA score correlated with clinical and radiographic evidence of disease,. Several patients had high disease activity scores that preceded clinical symptoms, indicating prognostic capabilities. The MSDA test is increasingly integrated into clinical practice, offering improved precision in care. This interview took place during the annual ACTRIMS Forum 2024.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Ferhan Qureshi is an employee of Octave Bioscience.